One of the most well-documented gain-of-function (GOF) mutations in the JAK-STAT pathway is JAK2-V617F, which is prevalent in myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and primary myelofibrosis [63–66]. This evidence concerns the gene SOAT1 and myeloproliferative disorder.